Stocks · News reference
Krystal Biotech shares are trading lower after the company announced mixed Q2 financial results.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 3, 2026, 11:58 AM
- Checked
- Aug 3, 2026, 11:58 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Citigroup Maintains Buy on Krystal Biotech, Raises Price Target to $386
Citigroup analyst Yigal Nochomovitz maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $378 to $386.
Read original at benzinga8-K filing — Krystal Biotech, Inc. (KRYS)
Filed: 2026-08-03 AccNo: 0001711279-26-000058 Size: 587 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar